GlassScriptPhysician profile
Keyonia Y Johnson
NPI 1891123659
$3,836.81
in general payments reported to CMS, 2019-2025
30 companies · $617 in 2025
The $617 reported for 2025 was more than what 78% of Family providers received nationally (typical 2025 total: $167).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $1,014 · 2022: $644 · 2023: $980 · 2024: $582 · 2025: $617.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,179.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,179.20 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $505.52 | 2021-2025 | |
| Lilly USA, LLC | $448.90 | 2021-2024 | Mounjaro, Jardiance, Emgality |
| Novo Nordisk INC | $426.80 | 2021-2025 | Ozempic, Rybelsus, Wegovy |
| Boehringer Ingelheim Pharmaceuticals, INC. | $331.45 | 2021-2025 | Jardiance |
| Astrazeneca Pharmaceuticals LP | $267.62 | 2021-2025 | Breztri, Airsupra, Fasenra |
| Abbott Laboratories | $234.04 | 2021-2025 | Freestyle Libre 3, Proclaim, Freestyle Libre 2 |
| Otsuka America Pharmaceutical, INC. | $167.27 | 2023-2025 | Rexulti |
| Dexcom, INC. | $159.94 | 2021-2025 | Dexcom G6 Transmitter |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $147.75 | 2021-2025 | Xifaxan, Trulance |
| Sanofi-Aventis U.S. LLC | $104.10 | 2021-2023 | |
| Merck Sharp & Dohme LLC | $92.45 | 2021-2022 | |
| Bayer Healthcare Pharmaceuticals INC. | $83.93 | 2023-2025 | |
| Lundbeck LLC | $82.39 | 2023-2025 | Rexulti |
| Novartis Pharmaceuticals Corporation | $80.72 | 2021-2022 | |
| Esperion Therapeutics, INC. | $79.62 | 2021-2024 | Nexletol |
Show all 30 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Pfizer INC. | $69.48 | 2021-2024 | |
| Janssen Pharmaceuticals, INC | $69.16 | 2021 | |
| Xeris Pharmaceuticals, INC. | $68.20 | 2021-2025 | Gvoke Hypopen |
| Takeda Pharmaceuticals U.S.A., INC. | $61.53 | 2021 | |
| Glaxosmithkline, LLC. | $59.27 | 2021-2024 | Arexvy, Shingrix |
| Amgen INC. | $46.58 | 2022-2024 | Repatha, Otezla |
| Inari Medical, INC. | $41.52 | 2023 | Flowtriever Catheter, S, Ct Thrombectomy System Kit |
| Nestle Healthcare Nutrition INC. | $34.87 | 2021-2023 | |
| Corcept Therapeutics | $31.88 | 2025 | Korlym |
| Exact Sciences Corporation | $31.61 | 2024-2025 | The Cologuard Plus Collection Kit, Cologuard Collection Kit |
| Edwards Lifesciences Corporation | $30.02 | 2025 | Edwards Sapien 3 Transcatheter Heart Valve (Thv) |
| Amarin Pharma, INC. | $26.95 | 2022 | |
| Cranial Technologies, INC | $18.91 | 2024 | Doc Band |
| Alnylam Pharmaceuticals INC. | $18.83 | 2024 | Onpattro |
| Teva Pharmaceuticals USA, INC. | $15.50 | 2023 | Ajovy |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Keyonia Johnson listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.